AVACOPAN

Brand name:

• Tavneos®

Pharmaceutical company:

Seqirus (Australia) Pty Ltd

Condition/indication:
(therapeutic use)

• Granulomatosis with polyangiitis and microscopic polyangiitis

PBAC Submission type:

New PBS listing (Standard Re-entry Pathway)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2024

Related medicines:

• AVACOPAN

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

03/06/2024

Lodgement of required documentation:

11/06/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 31/07/2024

Status:

Finalised

Government processes:

Commenced on 01/08/2024

Medicine listed on the PBS:

01/10/2024 (see PBS schedule)

---